Stevanato Group S P A Stock Price, News & Analysis

Stevanato Group (NYSE: STVN) reported strong Q1 2025 financial results with revenue increasing 9% to €256.6 million. The growth was primarily driven by an 11% increase in the Biopharmaceutical and Diagnostic Solutions (BDS) Segment, while the Engineering Segment saw a 4% decline. High-value solutions represented 43% of total revenue, reaching €110.3 million. The company's gross profit margin improved by 80 basis points to 27.2%, and adjusted EBITDA margin increased 100 basis points to 22.4%. For fiscal 2025, Stevanato maintains its revenue guidance of €1,160-1,190 million but updated its adjusted EBITDA guidance to €288.5-301.8 million and adjusted EPS to €0.50-0.54 to reflect tariff impacts. The company generated strong free cash flow of €29.7 million in Q1 2025, with cash and cash equivalents of €90.7 million and net debt of €300.2 million at quarter-end.

Stevanato Group (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, at 6:30 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a management presentation with accompanying slides. These materials will be available on the company's Investor Relations website under the 'Financial Results' section.

Participants can access the call through pre-registration, direct dial-in numbers available for Italy, United Kingdom, and United States, or via a live webcast. A replay of the webcast will be archived for three months on the company's website.

Stevanato Group (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences industries, has announced its participation in the KeyBanc Capital Markets Healthcare Forum.

The event is scheduled for March 18-19, 2025, with the company's presentation set for Tuesday, March 18, at 3:00 p.m. ET. Investors and interested parties can access the live webcast through the 'Investors' section of Stevanato's website at www.stevanatogroup.com. The presentation recording will remain available for approximately 90 days following the event.

Stevanato Group (NYSE: STVN) reported record revenue of €1,104 million for fiscal year 2024, marking a 2% increase from the previous year. The company's fourth quarter revenue grew 3% to €330.6 million, with high-value solutions representing 40% of total revenue.

Key financial metrics for FY2024 include:

• Adjusted EBITDA margin of 23.5%
• Diluted EPS of €0.43 and adjusted diluted EPS of €0.48
• High-value solutions revenue increased 15% to €422.3 million
• Biopharmaceutical and Diagnostic Solutions segment grew 6% to €933.7 million
• Engineering segment declined 17% to €170.3 million

For 2025, the company projects revenue between €1,160-1,190 million, adjusted EBITDA of €293.0-306.3 million, and adjusted diluted EPS of €0.51-0.55.

Stevanato Group (NYSE: STVN), a leading provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 6, 2025, at 6:30 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Management will reference a slide presentation available on the company's Investor Relations website. Participants can pre-register for immediate access to the call, while a live webcast will also be available. The webcast recording will be archived for three months on the company's Investor Relations section.

Stevanato Group (NYSE: STVN), a global leader in drug containment and delivery solutions for pharmaceutical, biotechnology, and life sciences industries, has announced its participation in the CJS Securities 25th Annual "New Ideas for the New Year" Investor Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 8:00 a.m. ET.

The company will provide a live webcast of the event through their website at www.stevanatogroup.com in the "Investors" section. Interested parties who cannot attend the live presentation can access a replay of the webcast, which will remain available for approximately 90 days following the event.

Stevanato Group (NYSE: STVN), a global leader in drug containment and delivery solutions, has announced its participation in three major investor conferences. The company will join the UBS Global Healthcare Conference in California on November 12, 2024, the Jefferies London Healthcare Conference on November 19, 2024, and the Citi 2024 Global Healthcare Conference in Miami on December 3, 2024.

Live webcasts of all presentations will be available on the company's website under the Investors section, with replays accessible for approximately 90 days following each event.

Stevanato Group (NYSE: STVN) reported Q3 2024 financial results with revenue increasing 2% to €277.9 million. High-value solutions represented 36% of total revenue. The company maintained its FY2024 revenue guidance of €1,090-1,110 million but lowered adjusted EBITDA guidance to €257-263 million and adjusted EPS to €0.47-0.49.

The Biopharmaceutical and Diagnostic Solutions segment grew 6% to €233.0 million, while Engineering segment declined 15% to €44.8 million. Gross profit margin decreased to 26.8% from 30.5% year-over-year, impacted by vial destocking and startup costs at the U.S. facility.

Stevanato Group (NYSE: STVN) has announced the expansion of its Vertiva® platform to include a 10mL option for on-body drug delivery. The platform offers a pre-filled and pre-loaded solution suitable for highly viscous biological drugs. Vertiva® features a single-use pod with a pre-filled cartridge and a reusable smart controller, allowing for versatile dosing profiles and easy home-based treatment.

The system's design simplifies treatment initiation and has shown positive results in a recent wearability study. It can record patient usage data and transfer it via Bluetooth to digital health applications. The platform's two-part system enhances sustainability by reducing electronic waste. Stevanato Group will collaborate with Thermo Fisher Scientific to bring Vertiva® 10mL to market, offering integrated capabilities from drug development to final packaging.